Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14759886 | 1.00 | EPHX1 (0.56) | EPHX1HTTTHRBMEN1KMT2A | |
| SCHEMBL27174198 | 1.00 | EPHX1 (0.56) | EPHX1HTTTHRBMEN1KMT2A | |
| SCHEMBL17479927 | 1.00 | EPHX1 (0.56) | EPHX1HTTTHRBMEN1KMT2A | |
| SCHEMBL17479925 | 1.00 | EPHX1 (0.56) | EPHX1HTTTHRBMEN1KMT2A | |
| SCHEMBL17479935 | 1.00 | EPHX1 (0.56) | EPHX1HTTTHRBMEN1KMT2A | |
| SCHEMBL17479934 | 1.00 | EPHX1 (0.56) | EPHX1HTTTHRBMEN1KMT2A | |
| SCHEMBL17479926 | 1.00 | EPHX1 (0.56) | EPHX1HTTTHRBMEN1KMT2A | |
| SCHEMBL19418439 | 1.00 | EPHX1 (0.56) | EPHX1HTTTHRBMEN1KMT2A | |
| SCHEMBL17738113 | 0.98 | HTT (0.56) | EPHX1HTTTHRBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29200158 | 0.98 | EPHX1 (0.54) | EPHX1HTTTHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| CN-115190901-A | Carbodiimide composition, curing agent composition, coating composition, and resin cured product | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| EP-3820871-B1 | NOVEL MOLECULES FOR TARGETING RIBOSOMES AND RIBOSOME-INTERACTING PROTEINS, AND USES THEREOF | IMMAGINA BIOTECHNOLOGY S R L (IT) | 2022-07-06 | — | — | EP | disclosed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2018118598-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-5986042-A | Cross-linked polymer | MITSUI CHEMICALS, INC. (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0856539-A1 | Cross-linked polymer | Mitsui Chemicals, Inc. (JP) | 1998-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | EPHX1 2839/4885HTT 868/4885THRB 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.